Oncotelic Therapeutics (Oncotelic Therapeutics) Short-Term Debt & Capital Lease Obligation : $10.68 Mil (As of Dec. 2023)

View and export this data going back to 1993. Start your Free Trial

What is Oncotelic Therapeutics Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Oncotelic Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $10.68 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Oncotelic Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.90 Mil.

Oncotelic Therapeutics Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Oncotelic Therapeutics's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncotelic Therapeutics Short-Term Debt & Capital Lease Obligation Chart

Oncotelic Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

0.96

4.65

8.99

11.26

10.68

Oncotelic Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															11.26	11.86	12.13	11.48	10.68

Oncotelic Therapeutics Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Oncotelic Therapeutics Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Oncotelic Therapeutics's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncotelic Therapeutics (Oncotelic Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncotelic Therapeutics Inc (OTCPK:OTLC) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

29397 Agoura Road, Suite 107, Agoura Hills, CA, USA, 91301

Website

https://www.oncotelic.com

Oncotelic Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer with a focus on rare pediatric cancers, and addressing the current global pandemic. OT-101 is its lead immuno-oncology drug candidate. OT-101 also has activity against SARS-CoV-2. Its other products under pipeline are Artemisinin, CA4P, and Oxi4503. Currently, the company generates revenues from rendering services to other third-party customers for the development of certain drug products or in connection with certain out-licensing agreements.

Executives

Vuong Trieu	officer: CHIEF EXECUTIVE OFFICER	4003 JIM BOWIE ROAD, AGOURA HILLS CA 91301
Saran Saund	officer: CHIEF BUSINESS OFFICER	C/O MATEON THERAPEUTICS INC., 29397 AGOURA RD SUTIE 107, AGOURA HILLS CA 91301
Amit B. Shah	officer: CHIEF FINANCIAL OFFICER	10 AGUILA, ALISO VIEJO CA 92656
Chulho Park	officer: CHIEF TECHNOLOGY OFFICER	701 GATEWAY BOULEVARD, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Maida Anthony E Iii	director	157 TECHNOLOGY DR, IRVINE CA 92618
Steven W King	director
David Diamond	director	29397 AGOURA RD., SUITE 107, AGOURA HILLS CA 91301
Fatih Uckun	10 percent owner, officer: Chief Medical Officer	701 GATEWAY BOULEVARD, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Chao Hsiao	10 percent owner	701 GATEWAY BOULEVARD, SUITE 201, SOUTH SAN FRANCISCO CA 94080
Larn Hwang	10 percent owner	C/O MARINA BIOTECH, INC., 17870 CASTLETON STREET, SUITE 250, CITY OF INDUSTRY CA 91748
Donald Rogers Reynolds	director	C/O WYRICK ROBBINS YATES & PONTON LLP, 4101 LAKE BOONE TRAIL, SUITE 300, RALEIGH NC 27607
Sandage Bobby W Phd	director	C/O 99 HAYDEN AVE, 1 LEDGEMONT CENTER, LEXINGTON MA 02173
Simon Pedder	director	1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Matthew M Loar	officer: Chief Financial Officer	505 PENOBSCOT DR, REDWOOD CITY CA 94063
Pamela Ha	officer: Controller	701 GATEWAY BOULEVARD, SUITE 210, SOUTH SAN FRANCISCO CA 94080